Dacomitinib Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Dacomitinib is used to treat non-small cell lung cancer that has spread (metastatic) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation gene. Your doctor will use a test to check for the mutation before you receive this medicine.Dacomitinib Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Dacomitinib Nitroso CAS NO:NA chemically represented as (E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide . Synchemia is the leading manufacturing and exporter of Dacomitinib Nitroso . We supply Dacomitinib Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142820 |
| CAS No | NA |
| Mol.F. | C10H16BN3O7S3 |
| Mol.Wt. | 397.24g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142821 |
| CAS No | NA |
| Mol.F. | C20H27N4O9S6 |
| Mol.Wt. | 659.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142822 |
| CAS No | NA |
| Mol.F. | C20H28N4O9S6 |
| Mol.Wt. | 660.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142823 |
| CAS No | NA |
| Mol.F. | C10H15N3O5S3 |
| Mol.Wt. | 353.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142824 |
| CAS No | NA |
| Mol.F. | C10H15N3O5S3 |
| Mol.Wt. | 353.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142825 |
| CAS No | NA |
| Mol.F. | C14H19N3O9S3 |
| Mol.Wt. | 469.50 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142826 |
| CAS No | NA |
| Mol.F. | C20H28N4O9S6 |
| Mol.Wt. | 660.82 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142827 |
| CAS No | 3028193-50-9 |
| Mol.F. | C20H20N2O2 |
| Mol.Wt. | 320.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142828 |
| CAS No | NA |
| Mol.F. | C18H24N4O6S2 |
| Mol.Wt. | 456.53g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142829 |
| CAS No | NA |
| Mol.F. | C20H28N4O8S3 |
| Mol.Wt. | 548.64 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142830 |
| CAS No | NA |
| Mol.F. | C20H28N4O8S3 |
| Mol.Wt. | 548.64 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142831 |
| CAS No | NA |
| Mol.F. | C10H165N3O4S |
| Mol.Wt. | 273.31g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142832 |
| CAS No | NA |
| Mol.F. | C24H23ClN2O2 |
| Mol.Wt. | 406.9 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142833 |
| CAS No | NA |
| Mol.F. | C22H24N4O8S |
| Mol.Wt. | 504.5 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142834 |
| CAS No | NA |
| Mol.F. | C23H24N4O10S |
| Mol.Wt. | 548.52g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142835 |
| CAS No | NA |
| Mol.F. | C22H26N4O9S |
| Mol.Wt. | 522.53 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |